Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Feb 27, 2020

(R) Cantargia publishes full year report for 2019

Feb 25, 2020

(R) Cantargia appoints Dr. Ignacio Garcia-Ribas as Chief Medical Officer

Feb 20, 2020

(R) Notice of extraordinary general meeting in Cantargia AB (publ)

Feb 19, 2020

(R) Cantargia has completed a directed share issue of approximately SEK 410 million

Feb 19, 2020

(R) Cantargia announces intention of a directed share issue

Feb 14, 2020

(R) Cantargia advances development of CAN04 through successful production scale up

Dec 5, 2019

(R) Cantargia selects CAN10 as development project in systemic sclerosis and myocarditis

Dec 2, 2019

(R) Cantargia reports positive interim data from ongoing phase IIa combination study with antibody CAN04

Nov 25, 2019

(R) Cantargia AB: Nomination Committee appointed ahead of 2020 Annual General Meeting

Nov 18, 2019

(R) Cantargia presents novel preclinical data on antibody CAN04 at PEGS Europe conference

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye